

DE GREEF RODERICK
Form 4
May 29, 2018

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
DE GREEF RODERICK

(Last) (First) (Middle)

C/O BIOLIFE SOLUTIONS,
INC., 3303 MONTE VILLA
PARKWAY, SUITE 310

(Street)

BOTHELL, WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

BIOLIFE SOLUTIONS INC [BLFS]

3. Date of Earliest Transaction
(Month/Day/Year)

05/25/2018

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___ 10% Owner
 Officer (give title below) ___ Other (specify below)

Chief Financial Officer

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	05/25/2019		M	10,000	\$ 1.64	24,583	D
Common Stock	05/25/2019		S	10,000	\$ 9.35	14,583	D
Common Stock	05/29/2019		M	15,000	\$ 1.64	29,583	D
Common Stock	05/29/2019		S	15,000	\$ 9.65	14,583	D

Edgar Filing: DE GREEF RODERICK - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option	\$ 1.64	05/25/2018		M	10,000	<u>(2)</u> 12/20/2021	Common Stock	10,000	
Employee Stock Option	\$ 1.8099					<u>(3)</u> 05/03/2026	Common Stock	234,000	
Employee Stock Option	\$ 1.76					<u>(4)</u> 03/04/2026	Common Stock	100,000	
Employee Stock Option	\$ 1.64	05/29/2018		M	15,000	<u>(2)</u> 12/20/2021	Common Stock	15,000	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
DE GREEF RODERICK C/O BIOLIFE SOLUTIONS, INC. 3303 MONTE VILLA PARKWAY, SUITE 310 BOTHELL, WA 98021			Chief Financial Officer	

Signatures

/s/ Roderick de Greef 05/29/2018

**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.64 to \$9.65, inclusive. The reporting person undertakes to provide to the Registrant, any security holder of the BioLife Solutions, Inc. (the

- (1) "Registrant"), or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- (2) The stock option vests and becomes exercisable as follows: 85,960 shares vested on March 8, 2018 and 85,959 shares will vest on March 8, 2019.
- (3) The stock option vests 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.
- (4) The stock option vests 25% on the first anniversary of the grant date and thereafter, in 36 equal monthly installments. Such options shall continue to vest regardless of whether Mr. de Greef's service with the Company continues.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.